Two independent studies show that OVA1 (Blood Multivariate Index Assay (MIA) for Ovarian Cancer Risk Assessment) improves ovarian cancer risk detection in women compared to alternative technology, according to Vermillion, a bioanalytical-based women’s health company focused on gynecologic disease.
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
